Horizon announces a U.S. physician survey illustrating the devastating impact of Thyroid Eye Disease (TED) on patient quality of life.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825). Under terms of the agreement, Horizon acquired Curzion for a $45 million upfront cash payment with additional payments contingent on the achievement of development and regulatory milestones. CZN001 was originally discovered and developed by Sanofi, which is eligible to receive contingent payments upon the achievement of development and commercialization milestones and royalties based on revenue thresholds.
Horizon Therapeutics (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming conferences:
Tim Walbert has been the CEO of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) since 2008. This analysis...
Shares of Horizon Therapeutics (NASDAQ: HZNP) are up by 16% as of 12:03 p.m. EDT on Wednesday following the company's release of its first-quarter earnings report. Investors were impressed with Horizon's quarterly update, with the company's revenue and earnings coming in much higher than analyst estimates. During the first quarter, Horizon's net sales were $355.9 million, representing a 27% year-over-year increase.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Down and Out Kidney, a campaign to highlight the damaging effects associated with the accumulation of uric acid and gout in people with chronic kidney disease (CKD).
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that multiple case series and studies will be presented at the Annual European Congress of Rheumatology (EULAR 2020), being held virtually June 3 - 6, 2020. Several presentations of clinical trial data and in-practice cases will provide results on KRYSTEXXA® (pegloticase injection) with commonly used immunomodulators to help more people with chronic gout refractory to conventional therapies – also known as uncontrolled gout – potentially achieve complete and durable response to treatment.
Earnings, Horizon Therapeutics, Biopharma, Biotech, Conference Call
Horizon Therapeutics plc (NASDAQ:HZNP) today announced it has been selected as one of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®.
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named No. 1 on the Great Place to Work® "Best Workplaces in Chicago 2020" list in the small and medium category. The list includes 39 other top small-to-medium sized companies, as well as 40 best large workplaces in the Chicago area.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
The pharmaceutical industry is part of the larger health care sector. Companies in the pharmaceutical industry research, develop, manufacture, and market medicines and drugs. The best-known pharmaceutical companies are, among others, Eli Lilly & Co.
Horizon announces new TEPEZZA pharmacokinetic data and Thyroid Eye Disease (TED) data published in the Journal of the Endocrine Society.
Q1 2020 Horizon Therapeutics PLC Earnings Call
Horizon Therapeutics gapped out of a four-month consolidation after reporting earnings that were more than double expectations
Horizon Therapeutics announces new pooled efficacy data for TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it, in partnership with Illinois Governor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology Innovation Organization (iBIO) Institute’s COVID-19 Response Fund.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2020 financial results will be released on Wednesday, May 6, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets are now available in the United States and can be ordered in 75 mg and 300 mg dosage strengths for adults and children one year of age and older living with nephropathic cystinosis. The U.S. Food and Drug Administration (FDA) approved this new dosage form in February 2020.